Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- And Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Infectious Diseases |
Vol/bind | 76 |
Udgave nummer | 7 |
Sider (fra-til) | 1328-1337 |
Antal sider | 10 |
ISSN | 1058-4838 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
Potential conflicts of interest . L. G. is a principal investigator of 2 phase III randomized controlled trials, funded by Unitaid and sponsored by Médecins Sans Frontières, testing shorter regimens for MDR/RR-TB including bedaquiline and delamanid. C. W. is on an advisory board for Pfizer on COVID-19 treatments (2 meetings in 2022 for which an honorarium was paid) and was recently lecturing on future pandemics for pulmonology specialists for Novartis (payment or honoraria). These sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. All other authors report no potential conflicts.
Publisher Copyright:
© The Author(s) 2022.
ID: 386452408